Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Nivolumab (Primary) ; Ramucirumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2018 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
- 12 Jul 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.